Weight loss service
Up to 17%* body weight reduction with Wegovy
Sourced directly from manufacturer Novo Nordisk
UK-based clinical expertise and monthly check-ins
No hidden fees (pay-as-you-go)
Wegovy tablets contain semaglutide, the same active ingredient as the Wegovy injection, and work by mimicking a natural hormone that signals to your brain when you're full, helping to reduce appetite and how much you eat.
The key difference from the injection is simply that the tablet is taken once-daily instead of a once-weekly injection. The tablet of course means no needles and there is also no refrigeration required.
Wegovy tablets received MHRA approval on 11 June 2026 and are expected to become available via private prescription in the UK within weeks. We will offer them to eligible patients as soon as they're ready to dispense.
Tablet-based weight loss treatments
Contain a GLP-1 receptor agonist (the same active ingredient as Wegovy)
Taken once daily orally, rather than once weekly by injection
Clinically tested with results comparable to injectable options
A non-injectable alternative for those who prefer not to use a pen
Easier to fit into everyday life for some people
No refrigeration or injection equipment required
The same clinically-led approach, in a simpler format
Oral GLP-1 tablets and injectable GLP-1 treatments are both effective, clinically-proven options. The right choice depends on your personal preferences and circumstances. Here is a quick comparison:
Wegovy tablets follow a gradual four-step titration schedule, starting at a low dose of 1.5mg daily and increasing at a minimum every four weeks, giving your body time to adjust and helping to minimise digestive side effects like nausea. The full maintenance dose of 25mg once daily is typically reached by week 16 of treatment if you respond well, and is taken long-term to maintain weight loss results.
The tablet is taken once daily on an empty stomach, with a small amount of water, followed by a 30-minute wait before eating, drinking anything other than water, or taking other oral medicines. This fasting window is important for the medication to absorb properly.
Everyone's journey is a little different, but most patients move through four stages with Wegovy tablets. Here's what you can expect along the way, from the first adjustments to long-term weight management.
Your body begins adjusting to semaglutide.
Mild nausea is common during this phase and usually settles quickly.
Appetite begins to reduce noticeably for most patients.
As your dosage increases you should see changes in your weight and your lifestyle.
Weight loss typically becomes more consistent at this stage.
Side effects, if any, are usually milder than in earlier weeks.
Full therapeutic dose for ongoing weight management.
This is the dose used throughout the OASIS 4 clinical trial, in which patients lost an average of 13.6% of body weight.
If you're currently taking Wegovy 2.4mg injections and want to switch to the tablet, you may be able to start at the full 25mg maintenance dose, skipping the titration steps entirely.
This would typically begin one week after your last injection, however is subject to a clinical review. One of our prescribers will assess your suitability as part of a switching consultation.
The tablet is not simply a like-for-like swap: the dosing is different (25mg oral vs 2.4mg injectable), the fasting requirements are new, and your clinician will want to ensure you're stable on your current dose before any change is made.
Wegovy tablets have a well-established safety profile, consistent with semaglutide in its injectable form, which has been used by millions of patients worldwide. In the OASIS 4 trial, serious adverse events were actually less common in the treatment group than in the placebo group (3.9% vs 8.8%), and fewer than 7% of patients stopped treatment due to side effects.
As with any prescription medicine, Wegovy tablets are not suitable for everyone. They should not be taken by people with a personal or family history of medullary thyroid cancer or MEN2, and are not currently approved for use during pregnancy. Our clinical team will assess your suitability before any prescription is issued.
Unit 1 Fifth Street
Trafford Park
Manchester
England
M17 1JX
MRPharmSGPhC
Registration Number: 2205052
Phlo Technologies Ltd
